Effects of Shengmai injection add-on therapy to chemotherapy in patients with non-small cell lung cancer: a meta-analysis
Shengmai injection (SMI) has shown promising outcomes in the management of non-small cell lung cancer (NSCLC). This meta-analysis aimed to investigate the add-on effects of SMI to chemotherapy in NSCLC patients.
A comprehensive literature search was performed in the Cochrane Library, PubMed, Embase, CNKI, VIP, and Wanfang up to December 2017. Only randomized controlled trials (RCTs) evaluating SMI in combination with chemotherapy versus chemotherapy alone in NSCLC patients were eligible. The outcome measures were quality of life, chemotherapy-induced grade 3/4 myelosuppression or gastrointestinal reactions, and objective tumor response (equals complete response plus partial response). Pooled risk ratio (RR) with 95% confidence interval (CI) was used to evaluate dichotomous and continuous outcome, respectively.
A total of 15 RCTs were included and analyzed. Meta-analysis showed that SMI combined with chemotherapy was associated with a significant improvement in Karnofsky Performance Status (RR 2.36; 95% CI 1.50–3.96) compared with the chemotherapy alone. Moreover, adjunctive treatment with SMI significantly reduced grade 3/4 myelosuppression (RR 0.61; 95% CI 0.46–0.81) and gastrointestinal reactions (RR 0.64; 95% CI 0.46–0.90). However, there was no significant difference in objective tumor response (RR 1.17; 95% CI 0.99–1.37) between two groups.
SMI add-on therapy appeared to be more effective in improving quality of life and reducing chemotherapy-induced adverse effects. However, more well-designed RCTs are warranted to confirm the findings of this meta-analysis because of the suboptimal methodological quality of the included trials.
KeywordsShengmai injection Non-small cell lung cancer Side effects Quality of life Meta-analysis
This work was supported by the National Natural Science Foundation of China (Foundation item number: 81673933).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval was not necessary due to this meta-analysis adopted the study-level data. This article adopted the study-level data.
- 4.Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D’Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, Doebele RC, Govindan R, Gubens MA, Hennon M, Horn L, Komaki R, Lackner RP, Lanuti M, Leal TA, Leisch LJ, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M (2017) Non-small cell lung Cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 15(4):504–535CrossRefGoogle Scholar
- 6.Jiao L, Dong C, Liu J, Chen Z, Zhang L, Xu J, Shen X, Che J, Yang Y, Huang H, Li H, Sun J, Jiang Y, Mao Z, Chen P, Gong Y, Jin X, Xu L (2017) Effects of Chinese medicine as adjunct medication for adjuvant chemotherapy treatments of non-small cell lung cancer patients. Sci Rep 7:46524CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Zhou GF, Li AJ (2003) Shengmai injection treatment for chemotherapy-reduced adverse reaction in non-small cell lung cancer 30 cases of patients. CJITWM 23(3):231–232Google Scholar
- 14.Li GX (2005) Clinical observation of Shengmai injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer. JETCM 14(3):233–234Google Scholar
- 15.Wang R, Wang ZX, Wang QC (2006) Shengmai injection combined with gemcitabine plus cisplatin cure advanced NSCLC. Suzhou Univ J Med Sci 26(4):631–633Google Scholar
- 16.Liang CW (2007) Clinical study on the treatment of advanced NSCLC with Shengmai injection combined with chemotherapy. J Anhui TCM Coll 26(3):15–18Google Scholar
- 17.Yao JT, Wang YZ, Zhang YJ, Wu HM, Zhao Z (2007) Clinical observation of Shengmai injection combined chemotherapy in advanced lung cancer. J Mod Oncol 15(8):1119–1120Google Scholar
- 18.Zhang QH (2008) Clinical observation of adjunctive treatment with Shengmai injection in non small cell lung cancer. Mod J Integr Tradit Chin West Med 17(24):3827–3828Google Scholar
- 19.Sun DB, Han Y (2009) The VEGF levels after pulse-activating ingection combined with interventional chemotherapy for non-small cell lung cancer. J Xinjiang Med Univ 32(9):1282–1284Google Scholar
- 20.Chen QS, Chen Y, Yang ZJ, Liu JB, Pei RQ (2011) The effect on quality of life to advanced stage non-small cell lung cancer patient treated with Shengmai injection combined chemotherapy. China J Chin Med 26(1):13–15Google Scholar
- 21.Lu XA (2011) Effect of Shengmai injection combined with chemotherapy on the quality of life and immune function in patients with advanced non-small cell lung cancer. Shaanxi J Tradit Chin Med 32(4):389–391Google Scholar
- 22.Bao YH (2011) Effect of Shengmai injection on the quality of life of patients with advanced non-small cell lung cancer receiving chemotherapy. Chin J Clin Res 24(11):1037–1038Google Scholar
- 23.Yang ZJ, Deng CM, Qiu YH, Mo BS (2012) Shengmai injection combined with NP regimen in the treatment of 30 cases of advanced non-small cell lung cancer. World Health Dig Med Periodieal 9(26):124–125Google Scholar
- 24.Wu Q, He X (2012) Clinical observation of Shengmai injection combined with chemotherapy in the treatment of middle to advanced lung cancer. Chin J Tradit Med Sci Technol 19(1):71–72Google Scholar
- 25.Wang DJ (2012) Efficacy of Shengmai injection combined with TP regimen in the treatment of advanced non-small cell lung cancer. Jilin Med J 33(11):2315–2316Google Scholar
- 26.Liu JY, Liu BY, Liu Y (2014) Clinical efficacy of Shengmai injection combined with gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer. China J Pharm Econ 9(11):211–212Google Scholar
- 27.Zhang CM (2016) Effect of Shengmai injection combined with chemotherapy in the treatment of patients with advanced non-small cell lung cancer. Chin Prim Health Care 30(7):92–93Google Scholar
- 29.Li Q, Liu H (2005) Pharmacological action and clinical application of Shengmai injection. Med Recapitulate 11(10):950–952Google Scholar